← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 382개
CGTBiologicstaleBeijing Boren HospitalPhase 1

Efficacy of LCAR-T2C CAR-T cells (Efficacy of LCAR-T2C CAR-T cells)

T Cell Lymphoma; T-cell Leukemia · T Cell Lymphoma

#TCellLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleBaylor College of MedicinePhase 1

Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells (Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleBiogenPhase 2

FCR + Lumiliximab (FCR + Lumiliximab)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
CGTBiologicstaleFred Hutchinson Cancer CenterPhase 1

FOLR1 CAR T-cells (FOLR1 CAR T-cells)

Recurrent Childhood Acute Myeloid Leukemia; Refractory Childhood Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 0%임상시험 1상태 RECRUITING
CGTBiologicstaleBenjamin TomlinsonPhase 1

Fully human anti CD19 CAR-T Cell Dose (Fully human anti CD19 CAR-T Cell Dose)

Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
ADCBiologicstalePfizerPreclinical

GO (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (GO))

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 ACTIVE
CGTBiologicstaleWugen, Inc.Preclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

HDMP + rituximab as a means of debulking prior to initiating venetoclax. (HDMP + rituximab as a means of debulking prior to initiating venetoclax.)

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia or Small Ly

#ChronicLymphocyticLeukemiaorSmal#Antibody#Phase1#항체#면역항체+2
효능 ORR 1%임상시험 1상태 RECRUITING
CGTBiologicstaleFondazione Policlinico Universi…Phase 2

Haplo SCT with NK cells (Haplo SCT with NK cells)

Acute Myeloid Leukemia; Myelodysplasia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleSeagen Inc.Phase 1

High dose cytarabine for consolidation (High dose cytarabine for consolidation)

Acute Myeloid Leukemia; Acute Myelogenous Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
CGTBiologicstaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 50%임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing Immunochina Medical Sci…Phase 1

IM19 CAR-T (IM19 CAR-T)

Hematological Malignancies · Leukemia

#Leukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
ADCBiologicstaleInstitut Paoli-CalmettesPhase 1

INA03 administration (INA03 administration)

Acute Lymphoblastic Leukemia Recurrent; Acute Lymphoblastic Leukemia, in Relapse · Acute Lymphoblastic Leukemia Recurrent

#AcuteLymphoblasticLeukemiaRecurr#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
AntibodystalePfizerPhase 3

Inotuzumab (Inotuzumab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
ADCBiologicstalePfizerApproved

Inotuzumab ozogamicin-dose level 1 (Inotuzumab ozogamicin-dose level 1)

Leukemia; Precursor b-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia

#Leukemia#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Intrathecal Rituximab (Intrathecal Rituximab)

Leukemia; Lymphoid Malignancies · Leukemia

#Leukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 1

Invivo CAR-T (Invivo CAR-T)

B-Acute Lymphoblastic Leukemia; B Cell Non-Hodgkin's Lymphoma · B-Acute Lymphoblastic Leukemia

#B-AcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
ADCBiologicstaleNovartis PharmaceuticalsPhase 1

JBH492 (JBH492)

Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
CGTBiologicstaleJuno Therapeutics, a Subsidiary…Phase 2

CD19-targeted CAR T cells (JCAR015, JCAR015 (CD19-targeted CAR T cells))

Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED

15 / 20 페이지

← 이전다음 →